

RESEARCH ARTICLE

Open Access

A preliminary study of individual cognitive behavior therapy for social anxiety disorder in Japanese clinical settings: a single-arm, uncontrolled trial

Naoki Yoshinaga^{1,2*}, Fumiyo Ohshima^{1,2}, Satoshi Matsuki^{1,2}, Mari Tanaka¹, Tomomi Kobayashi¹, Hanae Ibuki¹, Kenichi Asano², Osamu Kobori^{2,3}, Tetsuya Shiraishi^{2,4}, Emi Ito², Michiko Nakazato², Akiko Nakagawa², Masaomi Iyo^{3,4} and Eiji Shimizu^{1,2}

Abstract

Background: Cognitive behavior therapy (CBT) is regarded as an effective treatment for social anxiety disorder (SAD) in Europe and North America. Individual CBT might be acceptable and effective for patients with SAD even in non-Western cultures; therefore, we conducted a feasibility study of individual CBT for SAD in Japanese clinical settings. We also examined the baseline predictors of outcomes associated with receiving CBT.

Methods: This single-arm trial employed a 14-week individual CBT intervention. The primary outcome was the self-rated Liebowitz Social Anxiety Scale, with secondary measurements of other social anxiety and depressive severity. Assessments were conducted at baseline, after a waiting period before CBT, during CBT, and after CBT.

Results: Of the 19 subjects screened, 15 were eligible for the study and completed the outcome measures at all assessment points. Receiving CBT led to significant improvements in primary and secondary SAD severity (p s < .001). The mean total score on the Liebowitz Social Anxiety Scale improved from 91.8 to 51.7 (before CBT to after CBT), and the within-group effect size at the end-point assessment was large (Cohen's $d = 1.71$). After CBT, 73% of participants were judged to be treatment responders, and 40% met the criteria for remission. We found no significant baseline predictors of those outcomes.

Conclusion: Despite several limitations, our treatment—which comprises a 14-week, individual CBT program—seems feasible and may achieve favorable treatment outcomes for SAD in Japanese clinical settings. Further controlled trials are required in order to address the limitations of this study.

Trial registration: UMIN-CTR UMIN000005897

Keywords: Cognitive behavioral therapy, CBT, Social anxiety disorder, Social phobia, SAD, Japanese

* Correspondence: nao@chiba-u.jp

¹Department of Cognitive Behavioral Physiology, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan

²Research Center for Child Mental Development, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan

Full list of author information is available at the end of the article

Background

Social anxiety disorder (SAD; also known as social phobia) is characterized by fear of social situations involving performance or interaction [1]. SAD is one of the most prevalent psychiatric disorders in developed and developing countries [2] and is associated with substantial comorbidity (like many other anxiety and depressive disorders), functional disability (including social and occupational impairment), low health-related quality of life, and economic burden [3-5].

Pharmacotherapy and psychotherapy have been recommended as the first-line treatments for SAD [6-8]. In terms of pharmacotherapy, a growing database of randomized, controlled trials demonstrates that selective serotonin reuptake inhibitors (SSRIs) are effective and well tolerated [8]. In psychotherapy, cognitive behavioral therapy (CBT) has consistently been shown to be effective in randomized, controlled trials [9]. While no clear evidence has shown that the combination of SSRIs and CBT is more effective than single-modality treatment [10,11], CBT has a number of potential advantages over pharmacotherapy in the treatment of anxiety disorder: longer effects, fewer adverse effects, smaller relapse rates, and greater acceptability [12-14]. Pharmacotherapy has disadvantages such as more side effects and higher rates of relapse with the discontinuation of medication [15,16].

CBT was introduced into Japanese psychiatry in the late 1980s, and awareness of the effectiveness of CBT has spread, not only among professionals and academics but also among the general public. In April 2010, CBT for mood disorders (beyond that for anxiety disorders) began to be covered by Japan's national health insurance system. Nevertheless, a recent nationwide survey in Japan demonstrated that only 28% of medical facilities reported being able to conduct any form of psychotherapy satisfactorily [17] because of the limited availability of specialized practitioners. Only SSRIs (fluvoxamine and paroxetine) have been established as first-line treatments for Japanese patients with SAD as of 2012. It is therefore necessary to investigate whether CBT can achieve favorable treatment outcomes in Japanese SAD patients.

Previous reports about the effectiveness of CBT mostly came from Europe and North America, and CBT models and treatment components were developed in Western cultures with theoretical orientations typically constrained by Western conceptualizations of SAD. Cultural factors may be especially relevant to SAD pathology. For example, *taijin-kyofu-sho* (in Japanese, *taijin* means "interpersonal," *kyofu* means "fear," and *sho* means "syndrome"), which is listed in the appendix to DSM-IV, is said to be a culture-bound syndrome that is unique to East Asia. Although fear of interpersonal relations has been considered a

culture-bound syndrome [18-20], it can also be classified under existing categories in the DSM-IV-TR [21-23]. The notion that fear of interpersonal relations is purely a culture-bound syndrome does not always hold true. Despite differences between the conceptualizations of SAD and *taijin-kyofu-sho*, patients suffering from SAD in different parts of the world share many features in common, and similar assessments and treatments have been utilized across the world [24].

Only Chen and colleagues [25-27] showed that group CBT can bring about a similar degree of symptom reduction for Japanese patients as for Western patients with SAD. However, no study has tested the effectiveness of individual CBT for SAD in Japan. It is necessary to investigate whether individual CBT can achieve favorable treatment outcomes in Japanese patients with SAD, because some recent studies from Europe and North America have suggested that individual CBT is more effective than group CBT [28,29]. In addition, SAD has commonly been found to be highly comorbid with other Axis-I disorders, such as depression, bipolar disorder, and other anxiety disorders. Therefore, it is also important to understand how comorbidity and other clinical demographics affect treatment outcomes for SAD in clinical settings.

Thus, the purposes of this study are to report the preliminary outcomes of an individual CBT program for SAD in Japanese clinical settings and to examine the baseline predictors of the short-term outcomes associated with receiving CBT. The hypothesis is that individual CBT will be associated with decreased SAD severity in Japanese clinical settings and achieve comparable effectiveness to applications reported in Western settings.

Methods

Participants

The criteria for inclusion in this study were a primary diagnosis of SAD according to the DSM-IV, age of 18–65 years, and at least moderately severe SAD (on the basis of a Liebowitz Social Anxiety Scale [LSAS] score ≥ 50) [30,31]. Because Sugawara et al. (2012) reported that the mean total LSAS score was 42.4 (average SD = 27.5) in healthy Japanese community-dwelling subjects ($N = 929$) [32], we set a cutoff score of 50 on the LSAS for screening patients as suffering from moderate–severe symptoms of SAD. So that the study population would reflect routine clinical practice, comorbid diagnoses were permitted if clearly secondary (i.e., the SAD symptoms were both the most severe and the most impairing).

The exclusion criteria were psychosis, pervasive developmental disorders/mental retardation, autism spectrum disorders (Autism Spectrum Quotient ≥ 32) [33], current high risk of suicide, substance abuse or dependence in

the past 6 months, antisocial personality disorder, unstable medical condition, pregnancy, or lactation.

All patients were evaluated by a psychiatrist using the Structured Clinical Interview for Axis I Disorders (SCID-I) [34]. All patients were also screened for autism spectrum disorder with the Autism Spectrum Quotient [33] and the avoidant personality disorder section of the SCID-II [35], because those measures show some overlap with social-anxiety features and cannot be screened using SCID-I. Treatment history was confirmed by the prescribing clinician and by chart review.

Interventions

The CBT intervention was conducted in 14 weekly 90-minute sessions. Because the CBT model developed by Clark and Wells [36] has shown excellent treatment outcomes [28,29,37-39], our CBT program is based on the model of Clark and Wells. The main steps in treatment were as follows. The main steps in treatment were as follows: (a) developing an individualized version of the cognitive-behavioral model of SAD; (b) conducting role-play-based behavioral experiments with and without safety behaviors; (c) restructuring distorted self-imagery using videotape feedback; (d) practicing external focus and shifting attention; (e) behavioral experiments to test negative beliefs; (f) modifying problematic pre- and post-event processing; (g) discussing the differences between self-beliefs and other people's beliefs (reflected in survey results); (h) dealing with the remaining assumptions (schema work); (i) rescripting early memories linked to negative images in social situations; and (g) preventing relapse. Homework was assigned after every session.

Therapist and quality control

The CBT intervention was delivered by 6 therapists (3 clinical psychologists, 1 nurse, 1 psychiatrist, and 1 psychiatric social worker) who were experienced in the use of CBT for anxiety disorders and had completed the CBT training program at Chiba University (Chiba Improving Access for Psychological Therapies project). To check adherence to the protocol and assist with planning future sessions for each treatment, all therapists attended weekly group supervision sessions with other therapists and supervision sessions with a senior supervisor (ES). The senior supervisor also checked the quality of their CBT on the basis of the Cognitive Therapy Scale-Revised [40].

Outcomes

The primary outcome measure was self-reported symptoms of social anxiety, as measured on the LSAS [30], which is the most frequently used scale for the assessment of SAD. To assure comparability with previous CBT studies using the model of Clark and Wells, patients also completed additional self-report measures of

SAD severity: the Social Phobia Scale/Social Interaction Anxiety Scale (SPS/SIAS) [41], the Fear of Negative Evaluation Scale (FNE) [42], and the Fear Questionnaire – Social Phobia subscale (FQ-SP) [43]. Good reliability and validity of the Japanese versions have been reported for the LSAS, SPS, SIAS, and FNE [44-46].

Study design

This study was conducted as a single-arm, open trial to report the preliminary outcomes and the feasibility of a CBT intervention for SAD in Japanese clinical settings. Because this study was the first trial to employ an individual CBT intervention for SAD in East Asia (particularly in Japan), a single-arm trial examining baseline predictors rather than an efficacy trial is an appropriate design [47].

After enrolling in the study, patients were placed on a 2-week waiting period to establish the baseline stability of their symptoms. At the end of the waiting period, the patients received a CBT intervention for 14 weeks. Concomitant medications were permitted if the dose had been stable for at least 4 weeks prior to study entry and remained stable throughout the study. Assessments were conducted at baseline (week 0), pre-CBT (before session 1/week 2), mid-CBT (after session 7/week 9), and post-CBT (after session 14/week 16) time points.

This study was conducted at the psychiatric outpatient section at Chiba University Hospital and was performed in compliance with the Helsinki Declaration. The study protocol was approved by the Ethics Committee of the Chiba University Graduate School of Medicine (Reference number: 1216) and was registered in the national UMIN Clinical Trials Registry (ID: UMIN000005897).

Statistical analysis

The analysis was by intention-to-treat, and the last obtained data points for non-completers (because of adverse events, lack of compliance, etc.) were carried forward until the endpoint assessment. All statistical tests were two-tailed, and an α of .05 was employed. All of the data were analyzed using IBM SPSS Statistics for Windows, Version 20.0 (IBM, Armonk, New York, USA).

The baseline, pre-CBT, mid-CBT and post-CBT scores were analyzed between groups with single-factor (time) repeated-measures analyses of variance (ANOVAs) using Greenhouse–Geisser correction. Pairwise differences were measured using paired t-tests with Bonferroni correction to control for Type I error. The adjusted α value was $\alpha = .05 / 4 = .013$.

The mean changes in our primary outcome measure (LSAS) were calculated among patients showing both symptomatic response and remission. We established the following threshold for response and remission [48]: treatment-responder status was defined as a 31%-or-

greater reduction in LSAS score over the course of treatment, and remission was defined as a score of ≤ 36 on the LSAS. Moreover, patients who met the remission criteria were confirmed to no longer meet the criteria for SAD diagnosis using SCID-I interviews conducted by a skilled psychiatrist who was not a CBT therapist.

Moreover, the magnitude of the treatment effect was determined as the effect size $([M_{pre-CBT} - M_{post-CBT}] / SD_{pre-CBT})$ for each scale (LSAS, SPS, SIAS, FNE, and FQ-SP). According to Cohen [49], effect sizes are categorized as follows: small (.20-.49), medium (.50-.79), and large ($\geq .80$). Effect sizes reported in previous studies were calculated by different methods for various outcome measures. For a direct comparison among different CBT studies, we recalculated the effect sizes for each study based on these measures of SAD severity using the formula $[(M_{pre-CBT} - M_{post-CBT}) / SD_{pre-CBT}]$.

Finally, in order to elucidate the baseline predictors of treatment outcomes, multiple regression analyses were conducted with post-treatment LSAS scores as a dependent variable and the baseline demographic and clinical variables (gender, age, SAD subtype, presence of comorbid major depressive disorder, presence of another comorbid anxiety disorder, presence of avoidant personality disorder, age of onset, duration of SAD, employment status, marital status, educational status, use of medication, presence of

resistance to antidepressants) as independent variables while controlling for baseline LSAS scores.

Results

Treatment acceptability by the therapists

All of the participating therapists participated in the CBT training program (Chiba Improving Access for Psychological Therapies project) for 2 years and were able to adhere to the treatment protocol under weekly supervision. The mean CTS-R rating (adjusted for caseload) was 36.1 (on the basis of 15 randomly selected sessions; average $SD = .39$), which is greater than the threshold of competence expected in UK CBT training programs [40].

Baseline data

Participants were recruited according to the Consolidated Standards of Reporting Trials (CONSORT) guidelines, as presented in Figure 1. Of the 19 subjects screened, 15 were eligible for the study criteria and referred to the study. After enrolling in the study, no patient dropped out throughout the study. Table 1 shows the baseline demographic and clinical variables of the 15 patients enrolled in this study. The participants included 12 women (80%), and the patients' mean age was 29.9 years. All participants met the principal DSM-IV diagnostic criteria for SAD. Additional Axis I diagnoses for




Table 1 Baseline demographic and clinical characteristics (N = 15)

Variable		Value
Gender, female, N (%)		12 (80)
Age, years, Mean (SD)		29.9 (9.2)
Subtype, generalized, N (%)		13 (87)
Comorbid axis I diagnosis, N (%)	No comorbid condition (SAD only)	9(60)
	Mood disorder (major depression)	5 (33)
	Other anxiety disorder (panic)	1 (7)
Avoidant personality disorder, N (%)		4 (27)
Age of onset, years, Mean (SD)		17.6 (8.3)
Duration of SAD, years, Mean (SD)		12.5 (9.8)
Employment status, N (%)	Employed full-time	3 (20)
	Full-time student	6 (40)
	Part-time/homemaker	2 (13)
	Unemployed	4 (26)
Marital status, N (%)	Single	11 (73)
	Married	3 (20)
	Divorced	1 (7)
Educational background, N (%)	Junior high school	2 (13)
	High school	7 (44)
	<3 years of college/university	3 (20)
	≥3 years of college/university	3 (20)
Length of education, years, Mean (SD)		13.7 (1.8)
Current medication, N (%)	Benzodiazepines	5 (33)
	Antidepressants	5 (33)
	Both BZ and AD	3 (20)
	No medication	2 (13)
Resistance to antidepressants, N (%) ¹		11 (73)

¹: failure to respond to antidepressants: at least one SSRI was inadequate despite maximum dose and treatment duration of at least 12 weeks.
 Abbreviations: SAD, Social Anxiety Disorder; BZ, Benzodiazepines; AD, Antidepressants.

the patients included major depressive disorder (53%) and other anxiety disorders (e.g., panic disorder with agoraphobia; 7%). Other demographic and clinical variables of the participants are shown in Table 1.

Treatment outcomes

Table 2 presents the mean baseline, pre-CBT, mid-CBT, and post-CBT raw scores for the primary and secondary outcome measures. Single-factor repeated-measures

ANOVAs showed significant main effects of time on all outcome measures after the completion of treatment ($p < .001$). Pairwise comparisons of outcome measures indicated that the completers did not improve on any measure during the 2-week waiting period (baseline to pre-CBT); this indicates the baseline stability of their symptoms. On the other hand, the CBT intervention led to significant reductions in all outcome measures at the middle stage of treatment (pre-mid-CBT; $p < .05$) and a further significant reduction after treatment completion (mid-post-CBT; $p < .05$). On the basis of our primary outcome measure (LSAS), 11 patients (73.3%) were judged to be responders, and 6 of them (40%) met the criteria for SAD remission at the post-CBT evaluation.

As shown in Table 3, our pre-post-CBT effect sizes were large and provided comparable effectiveness to those obtained in previous studies of individual CBT, as determined using the model of Clark and Wells for all social-severity scales (effect sizes for LSAS = 1.71, SPS = 0.96, SIAS = 1.80, FNE = 1.82 and FQ-SP = 1.54).

Predictors of CBT outcomes

None of the baseline demographic and clinical variables (gender, age, SAD subtype, presence of comorbid major depressive disorder, presence of another comorbid anxiety disorder, presence of avoidant personality disorder, age of onset, duration of SAD, employment status, marital status, educational status, use of medication, and presence of resistance to antidepressants) were significant predictors of post-treatment LSAS score.

Discussion

This single-arm trial demonstrated that individual CBT, which was originally developed in Western countries, could lead to a significant reduction in SAD severity among Japanese patients. Moreover, our individual CBT demonstrated excellent acceptability, considering that there was no dropout among the participants.

Although the severity of SAD among our recruited patients was higher than that observed in previous studies (see Table 3), our effect size of 1.71 in terms of LSAS scores between the pre- and post-CBT observations is comparable to the effect sizes of 1.29–1.94 reported in previous clinical trials on CBT that used the model of Clark and Wells [28,29,37-39]. Comparison of effect sizes among various studies may be difficult, because the LSAS was administered by different methods (self-reported vs. clinician-administered) across the different studies. However, it is thought to be possible to compare these different types of LSAS scores, because scores on the self-report version of the LSAS correspond well to those on the clinician-administered version: In a previous study group, there was little difference between the two versions of the LSAS on any scale or subscale score [50].

Table 2 Repeated-measures analyses of variance (N = 15)

	Baseline Mean (SD)	Pre-CBT Mean (SD)	Mid-CBT Mean (SD)	Post-CBT Mean (SD)	Time (F)	η^2
LSAS	90.5 (21.4) ^a	91.8 (23.5) ^a	72.3 (21.5) ^b	51.7 (27.8) ^c	27.3 ^{***}	.66
SPS	42.4 (17.3) ^a	44.1 (18.7) ^a	32.8 (14.5) ^b	26.1 (17.6) ^c	18.9 ^{***}	.57
SIAS	57.7 (11.9) ^a	58.7 (12.0) ^a	47.7 (13.6) ^b	37.1 (19.0) ^c	33.3 ^{***}	.70
FNE	25.4 (3.9) ^a	25.2 (4.6) ^a	21.1 (6.2) ^b	16.9 (9.1) ^c	16.2 ^{***}	.54
FQ-SP	25.4 (8.1) ^a	28.5 (8.2) ^a	19.9 (9.5) ^b	16.0 (10.1) ^c	15.9 ^{***}	.54

*** Significant effect of time ($p < .001$).

Note: The same letters are not significantly different in pairwise comparisons.

Abbreviations: LSAS, Liebowitz Social Anxiety Scale; SPS, Social Phobia Scale; SIAS, Social Interaction Anxiety Scale; FNE, Fear of Negative Evaluation Scale; FQ-SP, Fear Questionnaire – Social Phobia subscale.

Our identification of possible predictors of response to CBT showed that the observed baseline demographic and clinical variables were not statistically significant predictors of LSAS scores after receiving CBT. The presence of comorbid mood disorders did not predict CBT outcomes in this study, and some previous studies have also demonstrated that individuals with comorbid mood disorders responded similarly to those with uncomplicated SAD [51,52]. However, Blanco (2003) found pre-treatment levels of self-reported depression to be the single most significant predictor of treatment outcomes [53]. Thus, it may be necessary to assess the level of severity of comorbid depression to facilitate the prediction of CBT outcomes in further studies. As for antidepressant history, it is reported that about 50% of individuals do not respond to antidepressants or have residual symptoms after first-line antidepressant treatment [54]. Most patients (73%) who participated in the current study showed resistance to first-line medications (at least one course of SSRI administration at the maximum dose for at least 12 weeks). One reason for this pattern of results is that only SSRIs (fluvoxamine and paroxetine) have been approved as treatments for SAD in Japan as of 2012. However, in the present study, CBT decreased SAD severity similarly in antidepressant-

resistant patients and antidepressant-responsive ones (i.e., the presence of antidepressant resistance was not a predictor of CBT outcomes). This finding suggested that individual CBT might have potential as a next-step strategy even for cases of antidepressant-resistant SAD.

Though the present study provided valuable information, its design imposes the following limitations. (1) This study included only a small sample size, which resulted in limited generalizability of its conclusions. (2) This was a single-center study; therefore, our participating population was somewhat different from those seen in routine clinical practice. Our study was designed to recruit patients similar to those seen in routine clinical practice; as a result, 40% had comorbid disorders, as is typical in clinical practice [55]. However, although the gender ratio of SAD cases is not typically skewed, the participants in this study were mostly women. The reason for this was that our outpatient section always took appointments during the daytime on weekdays; therefore, many men who worked weekdays could not participate in this study. (3) The lack of follow-up data limits the generalizability of the study's conclusions to longer-term outcomes. This is an important consideration in evaluating the effectiveness of CBT, because CBT has unknown characteristics in terms of longer-term effects, associated relapse rates, cost-

Table 3 Comparison of effect sizes among various clinical trials using the model of Clark and Wells

Study group	Present study			Clark et al. (2003)			Stangier et al. (2003)			Clark et al. (2006)			Mörtberg et al. (2007)			Stangier et al. (2011)			
CBT protocol	90 min 14 weeks			75 min 16 weeks			60 min 15 weeks			90 min 14 weeks			60 min 16 weeks			50–90 min 20 weeks			
	Pre	Post	ES	Pre	Post	ES	Pre	Post	ES	Pre	Post	ES	Pre	Post	ES	Pre	Post	ES	
LSAS	Mean (SD)	91.8 (23.5)	51.7 (27.8)	1.71	78.7 (25.6)	35.4 (22.9)	1.69				74.8 (24.1)	28.0 (17.7)	1.94	81.8 (21.1)	51.3 (27.9)	1.45	69.2 (23.4)	39.5 (21.1)	1.27
SPS	Mean (SD)	44.1 (18.7)	26.1 (17.6)	0.96	30.2 (14.8)	17.4 (13.2)	0.86	30.7 (10.2)	21.5 (12.6)	0.90	29.3 (13.5)	9.0 (6.0)	1.51	37.9 (12.5)	21.5 (13.8)	1.31			
SIAS	Mean (SD)	58.7 (12.0)	37.1 (19.0)	1.80	48.3 (12.3)	34 (13.9)	1.17	44.9 (10.8)	36.1 (14.8)	0.82	43.6 (17.8)	18.2 (10.0)	1.43	51.6 (15.5)	37.8 (17.7)	0.89			
FNE	Mean (SD)	25.2 (4.6)	16.9 (9.1)	1.82	25.2 (5.2)	19.5 (8.7)	1.09				23.1 (7.0)	12.9 (8.9)	1.46	23.3 (4.8)	18.5 (7.4)	1.00			
FQ	Mean (SD)	28.5 (8.2)	16.5 (10.7)	1.54	22.4 (6.4)	14.2 (7.0)	1.29							22.3 (8.6)	14.6 (7.6)	0.9			

Abbreviations: LSAS, Liebowitz Social Anxiety Scale; SPS, Social Phobia Scale; SIAS, Social Interaction Anxiety Scale; FNE, Fear of Negative Evaluation; FQ-SP, Fear Questionnaire – Social Phobia subscale; ES, Effect Size.

effectiveness characteristics, etc. (4) Psychotropic medication intake could not be discontinued before the start of this study. Though the inclusion of subjects using psychotropic medication limits the generalizability of the results, most patients (73%) already showed resistance to first-line medications (such as SSRIs) at baseline, and all of the patients showed baseline stability of their symptoms during the 2-week waiting period. Thus, it seemed that our individual CBT did indeed reduce SAD severity. (5) This was an uncontrolled study; therefore, we could not conclude definitively that our individual CBT was effective. It remains unknown whether the observed improvement in SAD severity is related to the natural course of SAD.

Future study should replicate these findings and address the limitations of this study in multi-center, randomized, controlled trials conducted with larger and more diverse samples across longer follow-up periods.

Conclusions

Despite several limitations, this study suggests via a single-arm design that individual CBT is a feasible treatment, even for Japanese patients with SAD. Further controlled trials that address the limitations of this study are required.

Availability of supporting data

The data sets supporting the results of this article are included within the article.

Consent

Written informed consent was obtained from the patient for publication of this report and any accompanying images.

Abbreviations

AD: Antidepressants; BZ: Benzodiazepines; CBT: Cognitive behavior therapy; ES: Effect size; FNE: Fear of negative evaluation; FQ-SP: Fear questionnaire – social phobia subscale; LSAS: Liebowitz social anxiety scale; SAD: Social anxiety disorder; SIAS: Social interaction anxiety scale; SSRI: Selective serotonin reuptake inhibitor; SPS: Social phobia scale.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

NY designed and managed the study, performed the statistical analyses, and drafted the manuscript. FO, SM, MT, HI, and TK performed the clinical treatment and management. KA, OK, TS, EI, AN, MN, and MI participated in the design of the study conception, administered supervised therapies, and coordinated the trial. ES administered supervised therapies, performed clinical investigation (diagnosis) and supervised the overall conduct of the study. All authors read, critically revised, and approved the final manuscript.

Acknowledgements

The primary sources for funding for this project were grants from Grant-in-Aid for Scientific Research from the Japanese Ministry of Health, Labour and Welfare (MHLW) (22SE1P0051). The MHLW played no role in the collection, management, analysis and interpretation of data; and had not any impact on the trial and the publication of the results. The authors express their gratitude to Dr. Tadashi Haraguchi for his statistical advice and to Ms. Naoko Takashima, Akemi Takeuchi, and Sachiko Yoshikawa for their

administrative assistance. Further, we would like to thank Editage for providing editorial assistance.

Author details

¹Department of Cognitive Behavioral Physiology, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan.

²Research Center for Child Mental Development, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan. ³Center for Forensic Mental Health, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan. ⁴Department of Psychiatry, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan.

Received: 17 November 2012 Accepted: 26 February 2013

Published: 28 February 2013

References

1. American Psychiatric Association: *Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition: DSM-IV-TR*. Washington: American Psychiatric Pub; 2000.
2. Stein DJ, Ruscio AM, Lee S, Petukhova M, Alonso J, Andrade LHSG, Benjet C, Bromet E, Demyttenaere K, Florescu S, de Girolamo G, de Graaf R, Gureje O, He Y, Hinkov H, Hu C, Iwata N, Karam EG, Lepine J-P, Matschinger H, Oakley Browne M, Posada-Villa J, Sagar R, Williams DR, Kessler RC: **Subtyping social anxiety disorder in developed and developing countries**. *Depress Anxiety* 2010, **27**:390–403.
3. Stein MB, Roy-Byrne PP, Craske MG, Bystritsky A, Sullivan G, Pyne JM, Katon W, Sherbourne CD: **Functional impact and health utility of anxiety disorders in primary care outpatients**. *Med Care* 2005, **43**:1164–1170.
4. Wang PS, Lane M, Olfson M, Pincus HA, Wells KB, Kessler RC: **Twelve-month use of mental health services in the United States: results from the National Comorbidity Survey Replication**. *Arch Gen Psychiatry* 2005, **62**:629–640.
5. Sareen J, Jacobi F, Cox BJ, Belik S-L, Clara I, Stein MB: **Disability and poor quality of life associated with comorbid anxiety disorders and physical conditions**. *Arch Intern Med* 2006, **166**:2109–2116.
6. Bandelow B, Zohar J, Hollander E, Kasper S, Möller H-J, Zohar J, Hollander E, Kasper S, Möller H-J, Bandelow B, Allgulander C, Ayuso-Gutierrez J, Baldwin DS, Buenvicior R, Cassano G, Fineberg N, Gabriels L, Hindmarch I, Kaiya H, Klein DF, Lader M, Lecrubier Y, Lépine J-P, Liebowitz MR, Lopez-Ibor JJ, Marazziti D, Miguel EC, Oh KS, Preter M, Rupprecht R, et al: **World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision**. *World J Biol Psychiatry* 2008, **9**:248–312.
7. Stein DJ, Baldwin DS, Bandelow B, Blanco C, Fontenelle LF, Lee S, Matsunaga H, Osser D, Stein MB, van Ameringen M: **A 2010 evidence-based algorithm for the pharmacotherapy of social anxiety disorder**. *Curr Psychiatry Rep* 2010, **12**:471–477.
8. Blanco C, Bragdon LB, Schneier FR, Liebowitz MR: **The evidence-based pharmacotherapy of social anxiety disorder**. *Int J Neuropsychopharmacol* 2013, **16**:235–249.
9. Hofmann SG, Smits JA: **Cognitive-behavioral therapy for adult anxiety disorders: a meta-analysis of randomized placebo-controlled trials**. *J Clin Psychiatry* 2008, **69**:621–632.
10. Blomhoff S, Haug TT, Hellström K, Holme I, Humble M, Madsbu HP, Wold JE: **Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia**. *Br J Psychiatry* 2001, **179**:23–30.
11. Davidson JRT, Foa EB, Huppert JD, Keefe FJ, Franklin ME, Compton JS, Zhao N, Connor KM, Lynch TR, Gadge KM: **Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia**. *Arch Gen Psychiatry* 2004, **61**:1005–1013.
12. Gelernter CS, Uhde TW, Cimboric P, Arnkoff DB, Vittone BJ, Tancer ME, Bartko JJ: **Cognitive-behavioral and pharmacological treatments of social phobia. A controlled study**. *Arch Gen Psychiatry* 1991, **48**:938–945.
13. Heimberg RG, Liebowitz MR, Hope DA, Schneier FR, Holt CS, Welkowitz LA, Juster HR, Campeas R, Bruch MA, Cloitre M, Fallon B, Klein DF: **Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12-week outcome**. *Arch Gen Psychiatry* 1998, **55**:1133–1141.
14. Hofmann SG, Barlow DH, Papp LA, Detweiler MF, Ray SE, Shear MK, Woods SW, Gorman JM: **Pretreatment attrition in a comparative treatment outcome study on panic disorder**. *Am J Psychiatry* 1998, **155**:43–47.

15. Lepola U, Bergtholdt B, Lambert B St, Davy KL, Ruggiero L: **Controlled-release paroxetine in the treatment of patients with social anxiety disorder.** *J Clin Psychiatry* 2004, **65**:222–229.
16. Liebowitz MR, Gelenberg AJ, Munjack D: **Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder.** *Arch Gen Psychiatry* 2005, **62**:190–198.
17. Ono Y, Furukawa TA, Shimizu E, Okamoto Y, Nakagawa A, Fujisawa D, Nakagawa A, Ishii T, Nakajima S: **Current status of research on cognitive therapy/cognitive behavior therapy in Japan.** *Psychiatry Clin Neurosci* 2011, **65**:121–129.
18. Prince R, Tcheng-Laroche F: **Culture-bound syndromes and international disease classifications.** *Cult Med Psychiatry* 1987, **11**:3–52.
19. Russell JG: **Anxiety disorders in Japan: a review of the Japanese literature on shinkeishitsu and taijinkyofusho.** *Cult Med Psychiatry* 1989, **13**:391–403.
20. Kleinknecht RA, Dinnel DL, Kleinknecht EE, Hiruma N, Harada N: **Cultural factors in social anxiety: a comparison of social phobia symptoms and Taijin kyofusho.** *J Anxiety Disord* 1997, **11**:157–177.
21. Suzuki K, Takei N, Kawai M, Minabe Y, Mori N: **Is taijin kyofusho a culture-bound syndrome?** *Am J Psychiatry* 2003, **160**:1358.
22. Choy Y, Schneier FR, Heimberg RG, Oh K-S, Liebowitz MR: **Features of the offensive subtype of Taijin-Kyofu-Sho in US and Korean patients with DSM-IV social anxiety disorder.** *Depress Anxiety* 2008, **25**:230–240.
23. Hofmann SG, Anu Asnaani MA, Hinton DE: **Cultural aspects in social anxiety and social anxiety disorder.** *Depress Anxiety* 2010, **27**:1117–1127.
24. Stein DJ: **Social anxiety disorder in the West and in the East.** *Ann Clin Psychiatry* 2009, **21**:109–117.
25. Chen J, Nakano Y, Ietsugu T, Ogawa S, Funayama T, Watanabe N, Noda Y, Furukawa TA: **Group cognitive behavior therapy for Japanese patients with social anxiety disorder: preliminary outcomes and their predictors.** *BMC Psychiatry* 2007, **7**:69.
26. Chen J, Furukawa TA, Nakano Y, Ietsugu T, Ogawa S, Funayama T, Watanabe N, Noda Y, Rapee RM: **Video feedback with peer ratings in naturalistic anxiety-provoking situations for social anxiety disorder: preliminary report.** *J Behav Ther Exp Psychiatry* 2010, **41**:6–10.
27. Watanabe N, Furukawa TA, Chen J, Kinoshita Y, Nakano Y, Ogawa S, Funayama T, Ietsugu T, Noda Y: **Change in quality of life and their predictors in the long-term follow-up after group cognitive behavioral therapy for social anxiety disorder: a prospective cohort study.** *BMC Psychiatry* 2010, **10**:81.
28. Mörtberg E, Clark DM, Sundin O, Aberg Wistedt A: **Intensive group cognitive treatment and individual cognitive therapy vs. treatment as usual in social phobia: a randomized controlled trial.** *Acta Psychiatr Scand* 2007, **115**:142–154.
29. Stangier U, Heidenreich T, Peitz M, Lauterbach W, Clark DM: **Cognitive therapy for social phobia: individual versus group treatment.** *Behav Res Ther* 2003, **41**:991–1007.
30. Liebowitz MR: **Social phobia.** *Mod Probl Pharmacopsychiatry* 1987, **22**:141–173.
31. Raj BA, Sheehan DV: **Social anxiety disorder.** *Med Clin North Am* 2001, **85**:711–733.
32. Sugawara N, Yasui-Furukori N, Kaneda A, Sato Y, Tsuchimine S, Fujii A, Danjo K, Takahashi I, Matsuzaka M, Kaneko S: **Factor structure of the Liebowitz Social Anxiety Scale in community-dwelling subjects in Japan.** *Psychiatry Clin Neurosci* 2012, **66**:525–528.
33. Baron-Cohen S, Wheelwright S, Skinner R, Martin J, Clubley E: **The autism-spectrum quotient (AQ): evidence from Asperger syndrome/high-functioning autism, males and females, scientists and mathematicians.** *J Autism Dev Disord* 2001, **31**:5–17.
34. First MB, Gibbon M: *User's Guide for the Structured Clinical Interview for DSM-IV Axis I Disorders SCID-I: Clinician Version.* Washington: American Psychiatric Pub; 1997.
35. First MB, Gibbon M: *User's Guide for the Structured Clinical Interview for DSM-IV Axis II Personality Disorders SCID-II.* Washington: American Psychiatric Pub; 1997.
36. Clark DM, Wells A: **A cognitive model of social phobia.** In *Social Phobia: Diagnosis, Assessment, and Treatment.* Edited by Heimberg RG, Liebowitz M, Hope DA, Schneier FR. New York: Guilford Press; 1995:69–93.
37. Clark DM, Ehlers A, McManus F, Hackmann A, Fennell M, Campbell H, Flower T, Davenport C, Louis B: **Cognitive therapy versus fluoxetine in generalized social phobia: a randomized placebo-controlled trial.** *J Consult Clin Psychol* 2003, **71**:1058–1067.
38. Clark DM, Ehlers A, Hackmann A, McManus F, Fennell M, Grey N, Waddington L, Wild J: **Cognitive therapy versus exposure and applied relaxation in social phobia: a randomized controlled trial.** *J Consult Clin Psychol* 2006, **74**:568–578.
39. Stangier U, Schramm E, Heidenreich T, Berger M, Clark DM: **Cognitive therapy vs interpersonal psychotherapy in social anxiety disorder: a randomized controlled trial.** *Arch Gen Psychiatry* 2011, **68**:692–700.
40. Blackburn I-M, James IA, Milne DL, Baker C, Standart S, Garland A, Reichelt FK: **The Revised Cognitive Therapy Scale (CTS-R): psychometric properties.** *Behav Cogn Psychother* 2001, **29**:431–446.
41. Mattick RP, Clarke JC: **Development and validation of measures of social phobia scrutiny fear and social interaction anxiety.** *Behav Res Ther* 1998, **36**:455–470.
42. Watson D, Friend R: **Measurement of social-evaluative anxiety.** *J Consult Clin Psychol* 1969, **33**:448–457.
43. Marks IM, Mathews AM: **Brief standard self-rating for phobic patients.** *Behav Res Ther* 1979, **17**:263–267.
44. Asakura S, Inoue S, Sasaki F, Sasaki Y, Kitagawa N, Inoue T, Denda K, Ito M, Matsubara R, Koyama T: **Reliability and validity of the Japanese version of the Liebowitz Social Anxiety Scale.** *Seishin Igaku (Clinical Psychiatry)* 2002, **44**:1077–1084.
45. Kanai Y, Sasakawa S, Chen J, Suzuki S, Shimada H, Sakano Y: **Development and validation of the Japanese version of Social Phobia Scale and Social Interaction Anxiety Scale.** *Shinshin-Igaku (Jpn J Psychosom Med)* 2004, **44**:841–850.
46. Ishikawa R, Sasaki K, Fukui I: **Standardization of Japanese version of FNE and SADS.** *Koudou Ryouhou Kenkyu (Jap J Behav Ther)* 1992, **18**:10–17.
47. Mohr DC, Spring B, Freedland KE, Beckner V, Areal P, Hollon SD, Ockene J, Kaplan R: **The selection and design of control conditions for randomized controlled trials of psychological interventions.** *Psychother Psychosom* 2009, **78**:275–284.
48. Bandelow B, Baldwin DS, Dolberg OT, Andersen HF, Stein DJ: **What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder?** *J Clin Psychiatry* 2006, **67**:1428–1434.
49. Cohen J: *Statistical Power Analysis in the Behavioral Sciences.* 2nd edition. Hillsdale: Erlbaum; 1988.
50. Fresco DM, Coles ME, Heimberg RG, Liebowitz MR, Hami S, Stein MB, Goetz D: **The Liebowitz Social Anxiety Scale: a comparison of the psychometric properties of self-report and clinician-administered formats.** *Psychol Med* 2001, **31**:1025–1035.
51. Marom S, Gilboa-Schechtman E, Aderka IM, Weizman A, Hermesh H: **Impact of depression on treatment effectiveness and gains maintenance in social phobia: a naturalistic study of cognitive behavior group therapy.** *Depress Anxiety* 2009, **26**:289–300.
52. Chambless DL, Tran GQ, Glass CR: **Predictors of response to cognitive-behavioral group therapy for social phobia.** *J Anxiety Disord* 1997, **11**:221–240.
53. Blanco C, Schneier FR, Schmidt A, Blanco-Jerez C-R, Marshall RD, Sánchez-Lacay A, Liebowitz MR: **Pharmacological treatment of social anxiety disorder: a meta-analysis.** *Depress Anxiety* 2003, **18**:29–40.
54. Van Ameringen M, Mancini C, Pipe B, Bennett M: **Optimizing treatment in social phobia: a review of treatment resistance.** *CNS Spectr* 2004, **9**:753–762.
55. Stein MB, Stein DJ: **Social anxiety disorder.** *Lancet* 2008, **371**:1115–1125.

doi:10.1186/1756-0500-6-74

Cite this article as: Yoshinaga et al.: A preliminary study of individual cognitive behavior therapy for social anxiety disorder in Japanese clinical settings: a single-arm, uncontrolled trial. *BMC Research Notes* 2013 **6**:74.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

